The Effect of Fedratinib, A Selective Inhibitor of Janus Kinase 2, on Weight and Metabolic Parameters in Patients with Intermediate- or High-risk Myelofibrosis

Douglas Tremblay; Lara Cavalli; Oumar Sy; Shelonitda Rose; John Mascarenhas

doi:10.1016/j.clml.2022.01.003

The Effect of Fedratinib, A Selective Inhibitor of Janus Kinase 2, on Weight and Metabolic Parameters in Patients with Intermediate- or High-risk Myelofibrosis

Douglas Tremblay, Lara Cavalli, Oumar Sy, Shelonitda Rose, John Mascarenhas

Research output: Contribution to journal › Editorial

1 Scopus citations

Original language	English
Pages (from-to)	e463-e466
Journal	Clinical Lymphoma, Myeloma and Leukemia
Volume	22
Issue number	7
DOIs	https://doi.org/10.1016/j.clml.2022.01.003
State	Published - Jul 2022

Keywords

JAKARTA
JAKARTA2
Metabolic effects
Ruxolitinib
Weight gain

Access to Document

10.1016/j.clml.2022.01.003

Cite this

@article{0ff63ae36eb14e7b9ca7938f713b46db,

title = "The Effect of Fedratinib, A Selective Inhibitor of Janus Kinase 2, on Weight and Metabolic Parameters in Patients with Intermediate- or High-risk Myelofibrosis",

keywords = "JAKARTA, JAKARTA2, Metabolic effects, Ruxolitinib, Weight gain",

author = "Douglas Tremblay and Lara Cavalli and Oumar Sy and Shelonitda Rose and John Mascarenhas",

note = "Funding Information: We thank the patients and families who made these trials possible. The original trials were supported by Sanofi S.A.; this reanalysis was funded by Bristol Myers Squibb. All authors contributed to and approved the manuscript; writing and editorial assistance were provided by Brian Kaiser and Sheila Truten of MEDCOMCO, funded by Bristol Myers Squibb.",

year = "2022",

month = jul,

doi = "10.1016/j.clml.2022.01.003",

language = "English",

volume = "22",

pages = "e463--e466",

journal = "Clinical Lymphoma, Myeloma and Leukemia",

issn = "2152-2650",

publisher = "Cancer Media Group",

number = "7",

}

TY - JOUR

T1 - The Effect of Fedratinib, A Selective Inhibitor of Janus Kinase 2, on Weight and Metabolic Parameters in Patients with Intermediate- or High-risk Myelofibrosis

AU - Tremblay, Douglas

AU - Cavalli, Lara

AU - Sy, Oumar

AU - Rose, Shelonitda

AU - Mascarenhas, John

N1 - Funding Information: We thank the patients and families who made these trials possible. The original trials were supported by Sanofi S.A.; this reanalysis was funded by Bristol Myers Squibb. All authors contributed to and approved the manuscript; writing and editorial assistance were provided by Brian Kaiser and Sheila Truten of MEDCOMCO, funded by Bristol Myers Squibb.

PY - 2022/7

Y1 - 2022/7

KW - JAKARTA

KW - JAKARTA2

KW - Metabolic effects

KW - Ruxolitinib

KW - Weight gain

UR - http://www.scopus.com/inward/record.url?scp=85123893899&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2022.01.003

DO - 10.1016/j.clml.2022.01.003

M3 - Editorial

C2 - 35120852

AN - SCOPUS:85123893899

SN - 2152-2650

VL - 22

SP - e463-e466

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

IS - 7

ER -